Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

News Conference News TCT 2025

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

Michael O'Riordan

October 27, 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

March 30, 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

News Conference News TCT 2024

ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients

October 30, 2024

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

News Conference News PCR London Valves 2023

Looking for a Winner Between Long-term TAVI Trials? Don’t, Experts Urge

November 27, 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

News Conference News TCT 2023

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

Michael O'Riordan

October 24, 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

News Conference News CRT 2023

New Durability Definitions Still Give Self-Expanding TAVI an Edge vs SAVR

Yael L. Maxwell

March 03, 2023

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

September 23, 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

News Conference News TCT 2022

Mix of Patient, Procedural, and Device Factors All Drove TAVI Advances

September 19, 2022

Surgical TAVI Explants Are Risky and Rising: STS Data Carry a Warning

News Conference News TCT 2022

Surgical TAVI Explants Are Risky and Rising: STS Data Carry a Warning

September 19, 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

News Conference News ACC 2022

Tricuspid Repair With Pascal Safe, Effective at 1 Year: CLASP TR

Yael L. Maxwell

April 05, 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

Positive Early Data for TAVR in Low-Risk Patients With Bicuspid Valves

News Conference News CRT 2020

Positive Early Data for TAVR in Low-Risk Patients With Bicuspid Valves

Michael O'Riordan

February 27, 2020

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

News Conference News TVT 2019

Surgical Risk Should Be ‘Off the Table’ When Deciding on Eligibility for TAVR

Michael O'Riordan

June 19, 2019

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

News Conference News TVT 2019

Transcarotid Bests Aortic/Apical for Alternative TAVR Access: TVT Registry

June 17, 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

News Conference News ACC 2019

Low-Risk Trials Cement a Role for TAVR Alongside—or in Place of—Surgery

Michael O'Riordan

March 17, 2019

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

News Conference News SCAI 2018

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

April 28, 2018

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

News Conference News TCT 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Yael L. Maxwell

November 09, 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

June 16, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.